JP2006507803A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006507803A5 JP2006507803A5 JP2004513328A JP2004513328A JP2006507803A5 JP 2006507803 A5 JP2006507803 A5 JP 2006507803A5 JP 2004513328 A JP2004513328 A JP 2004513328A JP 2004513328 A JP2004513328 A JP 2004513328A JP 2006507803 A5 JP2006507803 A5 JP 2006507803A5
- Authority
- JP
- Japan
- Prior art keywords
- fragment
- antibody
- diagnostic
- agent
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 41
- 238000001514 detection method Methods 0.000 claims 12
- 238000000034 method Methods 0.000 claims 11
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 9
- 108020001507 fusion proteins Proteins 0.000 claims 7
- 102000037865 fusion proteins Human genes 0.000 claims 7
- 229940124597 therapeutic agent Drugs 0.000 claims 7
- 230000001225 therapeutic effect Effects 0.000 claims 7
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 6
- 102100034256 Mucin-1 Human genes 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 239000002872 contrast media Substances 0.000 claims 5
- 238000001356 surgical procedure Methods 0.000 claims 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 3
- 108091034117 Oligonucleotide Proteins 0.000 claims 3
- 239000002254 cytotoxic agent Substances 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims 3
- 238000003745 diagnosis Methods 0.000 claims 3
- 239000002955 immunomodulating agent Substances 0.000 claims 3
- 229940121354 immunomodulator Drugs 0.000 claims 3
- 238000002347 injection Methods 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 108010032595 Antibody Binding Sites Proteins 0.000 claims 2
- 102100032528 C-type lectin domain family 11 member A Human genes 0.000 claims 2
- 101710167766 C-type lectin domain family 11 member A Proteins 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 108010063954 Mucins Proteins 0.000 claims 2
- -1 antibodies Substances 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000002584 immunomodulator Effects 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 238000002604 ultrasonography Methods 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 102000003951 Erythropoietin Human genes 0.000 claims 1
- 108090000394 Erythropoietin Proteins 0.000 claims 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 claims 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010070834 Sensitisation Diseases 0.000 claims 1
- 102000036693 Thrombopoietin Human genes 0.000 claims 1
- 108010041111 Thrombopoietin Proteins 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- 230000003302 anti-idiotype Effects 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 150000001553 barium compounds Chemical class 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000002532 enzyme inhibitor Substances 0.000 claims 1
- 229940105423 erythropoietin Drugs 0.000 claims 1
- 150000002259 gallium compounds Chemical class 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000003667 hormone antagonist Substances 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- 150000002497 iodine compounds Chemical class 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000005298 paramagnetic effect Effects 0.000 claims 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 1
- 230000008313 sensitization Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 150000003476 thallium compounds Chemical class 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38831302P | 2002-06-14 | 2002-06-14 | |
| US60/388,313 | 2002-06-14 | ||
| PCT/GB2003/002585 WO2003106497A1 (en) | 2002-06-14 | 2003-06-16 | Monoclonal antibody pam4 and its use for diagnosis and therapy of pancreatic cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006507803A JP2006507803A (ja) | 2006-03-09 |
| JP2006507803A5 true JP2006507803A5 (https=) | 2006-07-13 |
| JP5110768B2 JP5110768B2 (ja) | 2012-12-26 |
Family
ID=29736455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004513328A Expired - Fee Related JP5110768B2 (ja) | 2002-06-14 | 2003-06-16 | モノクローナル抗体ｐａｍ４ならびに膵臓癌の診断および治療のためのその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7238786B2 (https=) |
| EP (1) | EP1521775B1 (https=) |
| JP (1) | JP5110768B2 (https=) |
| KR (1) | KR101228124B1 (https=) |
| AU (1) | AU2003250367A1 (https=) |
| CA (1) | CA2489469C (https=) |
| RU (1) | RU2005100777A (https=) |
| WO (1) | WO2003106497A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8038994B2 (en) * | 1996-05-15 | 2011-10-18 | Quest Pharmatech Inc. | Combination therapy for treating disease |
| US7591994B2 (en) | 2002-12-13 | 2009-09-22 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
| US8658773B2 (en) | 2011-05-02 | 2014-02-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
| US20050260208A1 (en) * | 2002-04-11 | 2005-11-24 | Altarex Medical Corp. | Binding agents and their use in targeting tumor cells |
| US7172751B2 (en) * | 2003-06-13 | 2007-02-06 | Immunomedics, Inc. | D-amino acid peptides |
| ATE437657T1 (de) * | 2004-03-02 | 2009-08-15 | Cellectar Inc | Phospholipid-analoga für die behandlung von krebs |
| WO2006081553A2 (en) * | 2005-01-28 | 2006-08-03 | Ramot At Tel Aviv University, Ltd. | ANTI-MUC1 α/ß ANTIBODIES |
| JP2006248978A (ja) * | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
| JP3989936B2 (ja) * | 2005-04-07 | 2007-10-10 | 進 須永 | 抗腫瘍剤及び新規ｄｎアーゼ |
| EP1790664A1 (en) * | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| WO2007114861A2 (en) * | 2005-11-28 | 2007-10-11 | Zymogenetics, Inc. | Il-21 receptor antagonists |
| WO2007127813A2 (en) * | 2006-04-25 | 2007-11-08 | Drexel University | Modulation of signal transduction by site specific ultrasound agent delivery of transmembrane acting compounds |
| KR100954322B1 (ko) * | 2006-06-14 | 2010-04-21 | 주식회사 엘지생명과학 | 췌장암과 관련된 신규한 ｌｂｆｌ313 유전자 |
| WO2008091643A2 (en) * | 2007-01-23 | 2008-07-31 | Altarex Medical Corp. | In vitro culture system to evaluate synergy in targeting immune suppressive pathways concurrent to immunotherapy |
| EP1997832A1 (en) * | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| EP2604279A1 (en) | 2008-03-27 | 2013-06-19 | ZymoGenetics, Inc. | Compositions and methods for inhibiting PDGFRBETA and VEGF-A |
| US20160095939A1 (en) | 2014-10-07 | 2016-04-07 | Immunomedics, Inc. | Neoadjuvant use of antibody-drug conjugates |
| ES3000111T3 (en) | 2009-02-13 | 2025-02-27 | Immunomedics Inc | Intermediates for preparing conjugates with an intracellularly-cleavable linkage |
| ES2978177T3 (es) | 2009-12-02 | 2024-09-06 | Immunomedics Inc | Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer |
| CA2850572A1 (en) * | 2011-10-20 | 2013-04-25 | Esbatech, A Novartis Company Llc | Stable multiple antigen-binding antibody |
| WO2013082299A1 (en) | 2011-11-29 | 2013-06-06 | Als Therapy Development Institute | Targeting of t-lymphocytes to treat amyotrophic lateral sclerosis |
| CN104379169A (zh) | 2012-08-14 | 2015-02-25 | Ibc药品公司 | 用于治疗疾病的t-细胞重定向双特异性抗体 |
| WO2017004144A1 (en) | 2015-07-01 | 2017-01-05 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
| CN107753954A (zh) | 2012-12-13 | 2018-03-06 | 免疫医疗公司 | 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量 |
| CA2900955A1 (en) * | 2013-03-14 | 2014-10-02 | Oncomed Pharmaceuticals, Inc. | Met-binding agents and uses thereof |
| US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
| CA2938819A1 (en) | 2014-02-06 | 2015-08-13 | Medicinal Chemistry Pharmaceuticals, Co., Ltd. | Antibody to mucin 4 (muc4) glycopeptide and uses thereof |
| JP6447933B2 (ja) | 2014-02-21 | 2019-01-09 | アイビーシー ファーマスーティカルズ，インコーポレイテッド | Ｔｒｏｐ−２発現細胞に対する免疫応答を誘発することによる疾患治療 |
| CA2935748A1 (en) | 2014-02-25 | 2015-09-03 | Immunomedics, Inc. | Humanized rfb4 anti-cd22 antibody |
| EP3160504B1 (en) | 2014-06-24 | 2020-09-16 | Immunomedics, Inc. | Anti-histone therapy for vascular necrosis in severe glomerulonephritis |
| AU2016252771B2 (en) | 2015-04-22 | 2021-12-16 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells |
| JP6980980B2 (ja) | 2015-06-25 | 2021-12-15 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | 抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する |
| WO2022010797A2 (en) | 2020-07-07 | 2022-01-13 | Bionecure Therapeutics, Inc. | Novel maytansinoids as adc payloads and their use for the treatment of cancer |
| WO2022239720A1 (ja) | 2021-05-10 | 2022-11-17 | 公益財団法人川崎市産業振興財団 | 抗原への結合親和性を低減させた抗体 |
| WO2023056240A2 (en) | 2021-09-28 | 2023-04-06 | Frontaim Biomedicines, Inc. | Multiple formats of molecular complexes |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5776427A (en) * | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
| DE69534530T2 (de) * | 1994-08-12 | 2006-07-06 | Immunomedics, Inc. | Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper |
| US6261537B1 (en) * | 1996-10-28 | 2001-07-17 | Nycomed Imaging As | Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors |
| US6306393B1 (en) * | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| US7138103B2 (en) * | 1998-06-22 | 2006-11-21 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
| US7405320B2 (en) * | 1998-06-22 | 2008-07-29 | Immunomedics, Inc. | Therapeutic and diagnostic conjugates for use with multispecific antibodies |
| AU1728800A (en) * | 1998-11-18 | 2000-06-05 | Genentech Inc. | Antibody variants with higher binding affinity compared to parent antibodies |
| US6342219B1 (en) * | 1999-04-28 | 2002-01-29 | Board Of Regents, The University Of Texas System | Antibody compositions for selectively inhibiting VEGF |
| WO2002068471A2 (en) * | 2000-12-21 | 2002-09-06 | Bristol-Myers Squibb Company | Nucleic acid molecules and polypeptides for a human cation channel polypeptide |
-
2003
- 2003-06-16 RU RU2005100777/13A patent/RU2005100777A/ru not_active Application Discontinuation
- 2003-06-16 AU AU2003250367A patent/AU2003250367A1/en not_active Abandoned
- 2003-06-16 US US10/461,878 patent/US7238786B2/en not_active Expired - Fee Related
- 2003-06-16 CA CA2489469A patent/CA2489469C/en not_active Expired - Fee Related
- 2003-06-16 EP EP03760086.3A patent/EP1521775B1/en not_active Expired - Lifetime
- 2003-06-16 WO PCT/GB2003/002585 patent/WO2003106497A1/en not_active Ceased
- 2003-06-16 KR KR1020047020363A patent/KR101228124B1/ko not_active Expired - Fee Related
- 2003-06-16 JP JP2004513328A patent/JP5110768B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006507803A5 (https=) | ||
| JP2006513695A5 (https=) | ||
| US11230609B2 (en) | Humanised anti kallikrein-2 antibody | |
| JP5161254B2 (ja) | α−フェトタンパク質Ｉｍｍｕ３１抗体および融合タンパク質ならびにその使用方法 | |
| JP4963512B2 (ja) | 二重特異性抗体とともに使用される新規なペプチド型薬剤の製造及び使用 | |
| AU2003277087B2 (en) | Humanized monoclonal antiboby hPAM4 | |
| KR101228124B1 (ko) | 단클론 항체 ｐａｍ4 및 췌장암의 진단 및 치료를 위한이들의 용도 | |
| JP2006516086A5 (https=) | ||
| CN106573983B (zh) | 用于在癌症的预防和/或治疗中使用的放射性标记的抗体片段 | |
| US20120034158A1 (en) | Anti-met monoclonal antibody, fragments and derivatives thereof for use in tumor diagnosis corresponding compositions and kits | |
| JP2014524902A5 (https=) | ||
| TWI879889B (zh) | 用於分子接合或工程化的縱排重複癌症靶向胜肽及其於癌症診療中的用途 | |
| KR20180042226A (ko) | 암 치료에 사용하기 위한 방사성 표지된 항체 단편 | |
| JP2024511281A5 (https=) | ||
| JP7708374B2 (ja) | フィブリンに結合する抗体および当該抗体を含む医薬組成物 | |
| CN121342983A (zh) | 一种Claudin18.2靶向的纳米抗体及相关产品和应用 | |
| WO2023227644A2 (en) | Binding protein | |
| CN121360244A (zh) | 一种靶向Claudin18.2的纳米抗体在制备用于联合放疗治疗肿瘤或癌症的药物中的应用 | |
| IL165753A (en) | HUMANIZED MONOCLONAL ANTIBODY hPAM4, A CONJUGATE COMPRISING IT AND AN ANTIBODY COMPRISING THE SAME OR FRAGMENTS THEREOF |